Stephen Bloch

As an entrepreneur, venture capitalist and former practicing physician, Steve knows firsthand the challenges of building successful healthcare companies. Unfazed by complexity in healthcare, whether technical, regulatory, or market driven, Steve's mission has been to make healthcare delivery more effective and affordable.

Before co-founding EvolveImmune, Steve helped start and finance leading healthcare companies as a general partner at Canaan Partners. Steve currently serves on the boards of companies in biopharma (Liquidia (LQDA – NASDAQ, board chairman), digital health (Truveris, Ambra Health, Corvium and Genome Medical), and medical devices (Onkos Surgical). Past board roles include Amicus Therapeutics (FOLD-NASDAQ), Marinus Pharmaceuticals (MRNS-NASDAQ) and Advanced BioHealing (M&A with Shire). Steve is a member of Dartmouth Medical School’s Board of Advisors.

Before joining Canaan in 2002, Steve helped found and manage multiple start-ups, including Radiology Management Sciences (RMS) where he was CEO for 6 years, OmniSonics and TeleRad. Previously, Steve was a strategic pharmaceutical consultant for Arthur D. Little. Steve was an Ewing Marion Kauffman Fellow, an educational program to develop future leaders in venture capital.

Steve obtained his AB from Dartmouth College, a MA in the history of science from Harvard, and his medical degree from the University of Rochester. Steve completed his residency at Massachusetts General Hospital/Harvard Medical School (radiology) and Lenox Hill Hospital/Cornell Medical School (internal medicine).